Thematics Asset Management Has $4.34 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Thematics Asset Management raised its holdings in shares of Exact Sciences Co. (NASDAQ:EXASFree Report) by 36.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 58,597 shares of the medical research company’s stock after purchasing an additional 15,758 shares during the period. Thematics Asset Management’s holdings in Exact Sciences were worth $4,335,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in EXAS. Norges Bank acquired a new position in Exact Sciences during the 4th quarter valued at about $120,308,000. Jennison Associates LLC increased its stake in shares of Exact Sciences by 94.0% in the 4th quarter. Jennison Associates LLC now owns 1,360,917 shares of the medical research company’s stock valued at $100,681,000 after acquiring an additional 659,235 shares during the last quarter. Capital World Investors increased its stake in shares of Exact Sciences by 7.8% in the 4th quarter. Capital World Investors now owns 7,468,145 shares of the medical research company’s stock valued at $552,493,000 after acquiring an additional 539,498 shares during the last quarter. Artisan Partners Limited Partnership increased its stake in shares of Exact Sciences by 12.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 4,470,278 shares of the medical research company’s stock valued at $330,711,000 after acquiring an additional 508,764 shares during the last quarter. Finally, Qube Research & Technologies Ltd increased its stake in shares of Exact Sciences by 328.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 540,191 shares of the medical research company’s stock valued at $36,852,000 after acquiring an additional 414,059 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. William Blair reissued an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 22nd. Jefferies Financial Group initiated coverage on Exact Sciences in a report on Monday, June 3rd. They issued a “buy” rating and a $75.00 price objective for the company. Canaccord Genuity Group cut their price objective on Exact Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a report on Thursday, May 9th. BTIG Research cut their price target on Exact Sciences from $85.00 to $80.00 and set a “buy” rating for the company in a report on Thursday, May 9th. Finally, TheStreet downgraded Exact Sciences from a “c-” rating to a “d+” rating in a report on Monday, February 26th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, Exact Sciences presently has an average rating of “Moderate Buy” and an average price target of $93.07.

Get Our Latest Analysis on Exact Sciences

Exact Sciences Stock Performance

EXAS stock traded down $1.74 during trading hours on Friday, hitting $42.93. 1,632,394 shares of the stock were exchanged, compared to its average volume of 3,284,079. The company has a current ratio of 1.64, a quick ratio of 1.45 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $7.92 billion, a P/E ratio of -32.52 and a beta of 1.26. The company has a 50-day simple moving average of $58.36 and a two-hundred day simple moving average of $62.60. Exact Sciences Co. has a 12 month low of $42.72 and a 12 month high of $100.77.

Exact Sciences (NASDAQ:EXASGet Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, hitting the consensus estimate of ($0.50). Exact Sciences had a negative return on equity of 7.12% and a negative net margin of 9.48%. The firm had revenue of $637.52 million for the quarter, compared to analysts’ expectations of $624.95 million. On average, analysts forecast that Exact Sciences Co. will post -1.15 earnings per share for the current fiscal year.

Insider Activity at Exact Sciences

In related news, CEO Kevin T. Conroy sold 1,155 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total value of $69,473.25. Following the completion of the transaction, the chief executive officer now owns 1,156,191 shares of the company’s stock, valued at $69,544,888.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Exact Sciences news, CEO Kevin T. Conroy sold 1,155 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total transaction of $69,473.25. Following the completion of the transaction, the chief executive officer now owns 1,156,191 shares of the company’s stock, valued at $69,544,888.65. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Sarah Condella sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $70.00, for a total value of $140,000.00. Following the transaction, the executive vice president now directly owns 71,787 shares of the company’s stock, valued at approximately $5,025,090. The disclosure for this sale can be found here. Insiders sold a total of 5,498 shares of company stock valued at $370,105 over the last quarter. 1.36% of the stock is owned by corporate insiders.

Exact Sciences Company Profile

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Featured Stories

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASFree Report).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.